Clinical applications of magnetic drug targeting

Journal of Surgical Research

Volumn 95, Issue 2, 2001, Pages 200-206

  Lübbe, Andreas S ^a   Alexiou, Christoph ^b   Bergemann, Christian ^c  

^a Cecilien Klinik   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Bamberger Straße 51   (Germany)

Author keywords

Cancer treatment; Drug targeting; Epirubicin; Ferrofluids; Magnetic fields; Magnetism; Regional cancer treatment

Indexed keywords

ACLARUBICIN; ALBUMIN MICROSPHERE; ANTIBODY; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; ETHYL CELLULOSE; FLUOROURACIL; IRON DERIVATIVE; LIPOSOME; MITOMYCIN; NANOPARTICLE; NEODYMIUM; POLYLACTIC ACID; POLYMETHACRYLIC ACID; STARCH MICROSPHERE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VINBLASTINE SULFATE; VINDESINE;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL TRIAL; DESORPTION; DRUG ACCUMULATION; DRUG BINDING; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; EMULSION; HUMAN; MAGNET; MAGNETIC FIELD; MAGNETISM; MICROCAPSULE; NONHUMAN; PRIORITY JOURNAL;

EID: 0035747112     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2000.6030     Document Type: Article

References (42)

1. Annual variations in the vasopressin neuron population of the human suprachiasmatic nucleus
2. Circadian variation of mitrochondrial succinic dehydrogenase and microsomal cytochrome P-450 dependent monooxygenase activity in the liver of sexually immature and mature rats
3. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer
4. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival
5. Circadian phase dependent pharmacokinetics of disopyramide
6. Estrous influence on surgical cure of a mouse breast cancer
7. Season and cycle: Variation in presentation and response to therapy in premenopausal breast cancer
8. Temporal aspects of renal drug elimination
9. Glutathione content in human bone marrow and circadian stage relation to DNA synthesis
10. Circadian changes of drug disposition in man
11. Atrial natriuretic peptide and circadian blood pressure regulation: Clues from a chronobiologic approach
12. Circadian stage dependence of cis-diammine-dichloroplatinum lethal toxicity in rats
13. Cellular mechanisms involved in the action of anti cancer drugs
14. Mitotic indices of human bone marrow cells. I. Number and cytologic distribution of mitosis
15. Circadian and circannual variation of the cell cycle distribution in the mouse bone marrow
16. DNA synthesis and ploidy in non-Hodkin's lymphomas demonstrate variation depending on the circadian stage of cell sampling
17. Metabolism and mechanism of action of 5-fluorouracil
18. GABA is the principal neurotransmitter of the circadian system
19. Metabolism of pyrimidine analogues and their nucleosides
20. Circadian rythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice
21. Cancer control depends upon the circadian shape of continuous FUDR infusion
22. Comparison of different particles and methods for magnetic isolation of circulating tumor cells
23. Trends in drug targeting for cancer treatment
24. Magnetic guidance of drug carrying microspheres
25. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro
26. An approach to magnetically controlled cancer chemotherapy
27. Fibrinolysis by urokinase endowed with magnetic property
28. Preparation and characterization of dextran magnetite-incorporated thermosensitive liposomes: An on-line flow system for quantifying magnetic responsiveness
29. Targeting magnetic microsheres to brain tumors
30. MT: A magnetically targetable drug carrier for paclitaxel
31. 90Y radiotherapy
32. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy
33. Implications of heterogeneous bead behavior on cell mechanical properties measured with magnetic twisting cytometry
34. Drugs ten years later: Epirubicin
35. Clinical experiences with magnetic drug targeting: A phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors
36. Preclinical experiences with magnetic drug targeting: Tolerance and efficacy
37. Magnetically-controlled drug targeting
38. Physiological aspects in magnetic drug-targeting
39. Locoregional cancer treatment with "Magnetic Drug Targeting"
40. Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications